CHRFAM7A

Across TCGA pan-cancer cohorts, CHRFAM7A RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated CHRFAM7A data layer compared with 4 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CHRFAM7A RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CHRFAM7A expression acts as an unfavorable survival marker, although some lineages such as KIRP and CESC show a favorable association.

STAD, ACC, and KIRP are the cancer types where CHRFAM7A RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	All	0.501	0.703	<.001	106	view →
ACC	DFS	Tertile	All	0.353	0.775	<.001	93	view →
KIRP	DFS	Tertile	All	0.901	0.514	.001	40	view →
UVM	OS	Tertile	All	0.678	1.000	.009	25	view →
THCA	DFS	Quartile	II,III,IV	0.427	0.849	.001	21	view →
COAD	OS	Median	All	0.488	0.802	.006	19	view →
ESCA	OS	Median	IV	0.222	0.698	.006	12	view →
CESC	DFS	Quartile	IV	0.752	0.274	.025	12	view →
LUSC	DFS	Tertile	III,IV	0.433	0.961	.004	12	view →
HNSC	DFS	Median	III,IV	0.430	0.253	.011	11	view →
PRAD	DFS	Quartile	All	0.884	0.692	.020	10	view →
UCEC	OS	Tertile	All	0.850	0.914	.015	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

CHRFAM7A–STAD (OS)

Open the STAD breakdown →